olanzapine, Zyprexa, Zydis, Zyprexa Relprevv (cont.)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
SIDE EFFECTS:Common side effects seen with olanzapine are:
Several disorders of movement also may occur with olanzapine, for example, extrapyramidal effects (sudden, often jerky, involuntary motions of the head, neck, arms, body, or eyes). Tardive dyskinesia (involuntary movements of the mouth, tongue, jaw, or eyelids) also may occur in 1 in 100 patients receiving olanzapine. Some cases can be irreversible. The likelihood of developing tardive dyskinesia increases with prolonged treatment.
There may be an increased risk of elevated blood sugar levels and diabetes with olanzapine as well as the other antipsychotic medications in its class. Patients should be tested during treatment for elevated blood sugar. Additionally, persons with risk factors for diabetes, including obesity or a family history of diabetes, should have their fasting levels of blood sugar tested before starting treatment and periodically throughout treatment to detect the onset of diabetes. Any patient developing symptoms that suggest diabetes during treatment should be tested for diabetes.
Patients may develop severe sedation, coma, and or delirium after an injection of extended release olanzapine. Patients must be examined for 3 hours after receiving an injection.
Elderly patients with dementia related psychosis treated with antipsychotics are at an increased risk of death.
Olanzapine may increase prolactin levels. Increased prolactin levels may manifest as abnormal menstruation, sexual dysfunction, and breast enlargement.
GENERIC AVAILABLE: Yes
PREPARATIONS: Tablets: 2.5, 5, 7.5, 10, 15, 20 mg. Tablets (orally disintegrating): 5, 10, 15, 20 mg. Injection (immediate release): 10 mg vial. Suspension for Injection (extended release): 210, 300, and 405 mg (powder).
STORAGE: Tablets should be kept at room temperature, 20 C - 25 C (68 F - 77 F). Suspension is stored at room temperature not to exceed 30 C (86 F).
Medically Reviewed by a Doctor on 1/12/2015
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions